

REC Ref	IRAS No	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
17/LO/0584	173991	A mechanistic non-invasive imaging study of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography	Yes	08/03/2019	1	87	88	04/10/2018	10/12/2018	07/12/2018	11/12/2018	11/12/2018		11/12/2018	G - No patients consented	Neither
18/YH/0127	239022	instantaneous wave-free ratio guided Multi vessel revascularization During percutaneous coronary intervention for acute myocardial infarction	Yes	24/12/2018	26	42	68	09/03/2018	17/10/2018	21/05/2018	12/11/2018	12/11/2018		06/12/2018		
17/LO/0797	220423	A multi-center, non-randomized study to evaluate the safety and effectiveness of the Abre venous self-expanding stent system in patients with symptomatic iliofemoral venous outflow obstruction.	No					28/11/2016	05/10/2018	08/08/2017	17/01/2018		Sponsor dec	02/11/2018	B - Suspended by sponsor	Sponsor
16/SS/0014	187949	A double blind placebo controlled trial of a combination of methotrexate and gefitinib versus methotrexate alone as a treatment for ectopic pregnancy	No		1			15/11/2016	17/10/2018	14/10/2016	18/10/2018	18/10/2018		22/11/2018	D - Sponsor Delays	Sponsor
17/LO/0457	215990	The Bio-inspired Artificial Pancreas for the Home	Yes	20/07/2018	35	60	95	06/07/2017	16/04/2018			21/05/2018			G - No patients consented	Neither
18/SW/0103	200303	A phase II prospective randomised clinical study of endoscopic ultrasound guided radiofrequency ablation (EUS-RFA) for inoperable ductal pancreatic carcinoma	No		51			26/03/2018	11/04/2018	31/05/2018	11/04/2018	01/06/2018			A - Permissions delayed/denied	Neither
17/LO/0389	221666	Psilocybin for major depression: A randomized control trial	No		79			18/07/2018	14/08/2018	18/06/2018		01/11/2018			E - Staff availability issues	NHS Provid
18/LO/0761	231087	A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs)	Yes	06/03/2019	35	29	64	01/11/2018	01/01/2019	24/01/2019	30/01/2018	05/02/2019		05/02/2019		
17/SC/0090	215068	A trial using ctDNA blood tests to detect cancer cells after standard treatment to trigger additional treatment in early stage triple negative breast cancer patients (c-TRAK-TN)	No		195			23/06/2017	31/07/2018	05/07/2017		11/02/2019			C - Closed by sponsor	Sponsor
															H - Contracting delays	
18/LO/0217	235711	INvestigational Study Into Transplantation of the Uterus (INSITU)	No		32			24/01/2018	23/04/2018	28/02/2018	25/05/2018	25/05/2018		19/02/2019	H - Contracting delays	Neither
17/NE/0300	225917	A phase II, randomised, double-blind, placebo-controlled, parallel-group, multicentre study investigating the efficacy and safety of Sepranolone (UC1010) in patients with PMDD	Yes	04/07/2018	22	35	57	06/11/2017	08/05/2018	31/10/2017	30/05/2018	30/05/2018		18/06/2018		
18/LO/1063	236384	The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study-Actellion - AC-065A308	Yes	14/11/2018	38	40	78	16/10/2017	28/08/2018	12/07/2018	29/08/2018	05/10/2018			G - No patients consented	Neither
18/LO/1186	236886	PREvention of Stroke in Intracerebral haemorrhage survivors with Atrial Fibrillation (PRESTIGE-AF)	No		69			14/06/2018	04/01/2019	07/12/2018	06/03/2019	14/03/2019			D - Sponsor Delays	Sponsor
17/WM/0146	220303	A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease	Yes	30/05/2018	3	27	30	23/05/2017	30/04/2018	21/08/2017	23/05/2017	03/05/2018		08/05/2018		
17/LO/1660	223181	Feasibility of Improving Risk Stratification in Brugada Syndrome	Yes	05/10/2018	56	0	56	28/02/2018	10/08/2018	22/11/2017	05/10/2018	05/10/2018				
17/EE/0387	231908	Maraviroc Add-On Therapy for Steatohepatitis in HIV	Yes	19/06/2018	0	49	49	30/08/2017	01/05/2018	08/03/2018	01/05/2018	01/05/2018		03/05/2018		
18/LO/0745	231612	IL-1 Signal Inhibition in Alcoholic Hepatitis (Isaiah)	Yes	21/12/2018	32	46	78	05/04/2018	04/10/2018	11/07/2018	19/10/2018	05/11/2018			J - Other	Neither
17/YH/0329	216857	A randomized, double-blind, placebo-controlled, two-cohort parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's disease	No		38			31/07/2017	14/05/2018	28/11/2017	31/07/2017	21/06/2018		22/06/2018	I - Rare diseases	Neither
18/LO/0174	232220	SABRE- Serratus Anterior Block and catheter use in Rib fractures in the Emergency department	Yes	25/11/2018	36	130	166	15/11/2017	12/06/2018	02/03/2018	18/07/2018	18/07/2018			J - Other	Neither

17/LO/1693	233988	A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of two dosing regimens of continuous subcutaneous ND0612 infusion Given as adjunct treatment to oral levodopa in patients with Parkinson's Disease with motor fluctuations (iNDiGO)	No					04/10/2017	10/04/2018		04/10/2017				D - Sponsor Delays	Sponsor
18/EE/0005	232671	A MULTICENTER, OPEN-LABEL STUDY TO ESTIMATE THE EFFECT SIZES OF HRCT ENDPOINTS IN RESPONSE TO GLUCOCORTICOID INDUCTION THERAPY IN SUBJECTS WITH PULMONARY SARCOIDOSIS	No		104			10/11/2017	19/07/2018	19/07/2018		31/10/2018			D - Sponsor Delays	Sponsor
18/LO/0779	235161	A Randomized (1:1), Double blind, Multi center, Placebo Controlled Study Evaluating Intensive Chemotherapy With or Without Glasdegib (PF 0444913) or Azacitidine With or Without Glasdegib in Patients With Previously Untreated Acute Myeloid Leukemia.	No		163			18/12/2017	03/07/2018	15/06/2018	03/07/2018	13/12/2018		07/03/2019	D - Sponsor Delays	Sponsor
															I - Rare diseases	
18/LO/0700	238068	A Phase 1/2 Study of the Safety and Efficacy of a Single Dose of Autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hSPCs) in Subjects with Transfusion-Dependent $\beta$ Thalassemia.	Yes	01/04/2019	143	175	318	18/12/2017	18/05/2018	02/07/2018	13/09/2018	08/10/2018		22/03/2019	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/0270	228830	Can NIRS be used as an intra-operative monitor of spinal cord function and predict patient outcome after vascular surgery?	Yes	27/07/2018	31	70	101	06/04/2018	17/04/2018		18/05/2018	18/05/2018			F - No patients seen	Neither
18/LO/0070	238482	A Pivotal Clinical Trial of the Management of th Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System	Yes	20/09/2018	24	119	143	23/01/2018	30/04/2018	30/04/2018	10/05/2018	24/05/2018		24/05/2018	F - No patients seen	Neither
18/WS/0087	241031	Optimal duration of Cooling therapy in Mild Encephalopathy (COMET 1)	Yes	15/10/2018	7	70	77	02/05/2018	30/07/2018	18/06/2018	06/08/2018	06/08/2018		06/08/2018	J - Other	Neither
18/YH/0212	237279	A phase Ib study of Itacitinib, a JAK1 inhibitor, in advanced hepatocellular carcinoma	Yes	13/02/2019	5	72	77	14/08/2018	28/11/2018	14/08/2018	28/11/2018	03/12/2018		10/12/2018	G - No patients consented	Neither
17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebocontrolled, dose ranging study to investigate the efficacy and safety of LNPO23 in primary IgA nephropathy patients	No		7			15/01/2018	01/05/2018	04/12/2017		08/05/2018		08/05/2018	D - Sponsor Delays	Neither
18/LO/0666	242700	Extended Access of Mometinib for Subjects with Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).	Yes	18/10/2018	58	91	149	11/04/2018	22/05/2018	15/05/2018	13/07/2018	19/07/2018		26/09/2018	D - Sponsor Delays	Sponsor
															J - Other	
18/LO/0170	236855	A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in combination with Standard of Care as Adjuvant Therapy for Stage III-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)	Yes	01/02/2019	89	45	134	29/01/2018	20/09/2018	04/04/2018	11/12/2018	18/12/2018		18/12/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/LO/0376	236553	Investigating physiological effects of weight loss on male fertility	Yes	16/05/2018	27	8	35	23/03/2018	11/04/2018	11/04/2018		08/05/2018				
18/EE/0091	234395	A first in human, phase 1 safety study in two parts to determine the safety, tolerability and anti-cancer immuno-modulatory effects of MRx0518 in patients with solid tumours awaiting surgical removal of the tumour.	No		97			04/05/2018	14/11/2018	06/06/2018		19/02/2019		26/03/2019	D - Sponsor Delays	Sponsor
19/LO/0138	245920	Effect of EVOlocumab on CARotid plaque composition in asymptomatic carotid artery stenosis (EVOCAR-1)	No					30/10/2018	27/03/2019							
18/LO/1162	242411	A Study to Evaluate the Safety and Efficacy of Staged Bilateral ExAblate Treatment of Medication Refractory Bilateral Essential Tremor	Yes	17/01/2019	35	41	76	25/04/2018	02/11/2018	17/10/2018	07/12/2018	07/12/2018			G - No patients consented	Neither
18/EM/0153	240773	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency	No		38			16/05/2018	31/08/2018	28/08/2018	24/09/2018	08/10/2018			G - No patients consented	Neither

18/NW/0107	236834	PHIL evaluation in the endovascular treatment of intracranial cerebral ArterioVenous Malformation	No		39			26/02/2018	04/06/2018	14/05/2018	13/07/2018	13/07/2018		31/07/2018	F - No patients seen	Neither
															I - Rare diseases	
18/LO/0235	240315	An Open Label Extension Study of GBT440 Administered Orally to Patients with Sickle Cell Disease Who Have Participated in GBT440 Clinical Trials	No		60			28/02/2018	17/12/2018	17/04/2018				15/02/2019	D - Sponsor Delays	Sponsor
															J - Other	
18/LO/0512	196718	DICE Trial: An international multi-centre randomised phase II study to assess the efficacy of TAK228 in combination with intravenous weekly paclitaxel compared with weekly paclitaxel alone in women with advanced/recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high grade serous type, and carcinosarcoma)	Yes	11/09/2018	79	12	91	05/03/2018	12/06/2018	05/06/2018				30/08/2018	D - Sponsor Delays	Sponsor
18/NW/0109	234734	PHIL evaluation in the endovascular treatment of intracranial dural AVF	No		30			26/02/2018	12/09/2018	14/05/2018	12/09/2018	12/10/2018			G - No patients consented	Neither
18/LO/0393	240955	A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy via Zinc Finger Nuclease (ZFN) mediated targeted integration of SB-FIX in Subjects with Severe Haemophilia B	No		51			15/03/2018	25/07/2018	20/06/2018	04/07/2018	14/09/2018			D - Sponsor Delays	Sponsor
18/SS/0010	238051	A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations	No		98			05/02/2018	04/05/2018	21/03/2018	01/08/2018	10/08/2018		07/09/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/0919	235977	A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation	No		39			11/04/2018	22/10/2018	29/08/2018	19/11/2018	30/11/2018		07/01/2019	E - Staff availability issues	Neither
18/LO/0416	235395	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours	No					10/04/2018	30/07/2018	14/06/2018					Site declined to participate	
16/SS/0070	202282	PREvention of Complications to Improve Outcome in elderly patients with acute Stroke. A randomised, open, phase III, clinical trial with blinded outcome assessment.	No					12/07/2018	04/02/2019							
18/LO/0858	241447	A PHASE II, RANDOMIZED, ACTIVE-CONTROLLED, MULTI-CENTER STUDY COMPARING THE EFFICACY AND SAFETY OF TARGETED THERAPY OR CANCER IMMUNOTHERAPY GUIDED BY GENOMIC PROFILING VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH CANCER OF UNKNOWN PRIMARY SITE WHO HAVE RECEIVED THREE CYCLES OF PLATINUM DOUBLET CHEMOTHERAPY	Yes	18/10/2018	145	10	155	13/04/2018	16/05/2018	12/07/2018				08/10/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/LO/0995	244737	A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer	Yes	30/10/2018	129	18	147	13/04/2018	05/06/2018	20/09/2018	09/03/2018	12/10/2018		12/10/2018	D - Sponsor Delays	Sponsor
18/SC/0155	236211	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease	No		60			23/04/2018	21/06/2018	26/04/2018	07/08/2018	20/08/2018		01/02/2019	D - Sponsor Delays	Sponsor
18/LO/0719	235423	A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients with C3 Glomerulopathy (C3G)	No		3			19/10/2017	29/10/2018		17/10/2018	01/11/2018		05/11/2018	I - Rare diseases	Neither
18/NE/0136	240494	A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation	Yes	01/12/2018	183	30	213	02/05/2018	02/05/2018	13/07/2018	13/02/2018	01/11/2018		01/11/2018	D - Sponsor Delays	Sponsor
															G - No patients consented	

18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Dose Finding, Placebo Controlled, Safety, Efficacy and Pharmacokinetic Study of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	No					21/09/2018	21/09/2018	19/10/2018					D - Sponsor Delays	Sponsor
18/LO/1461	245412	A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)	No		120			06/04/2018	01/11/2018	19/10/2018	27/02/2019	01/03/2019		28/02/2019	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/YH/0014	224065	External frame versus internal locking plate for articular pilon fracture fixation: a multi-centre randomised controlled trial	No		89			10/10/2018	10/10/2018	13/02/2018		07/01/2019		21/01/2019	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/1338	247728	PROSTAGRAM - Prostate Screening Trial using A Group of Radiological Approaches including MRI and ultrasound	Yes	16/10/2018	12	27	39	10/07/2018	07/09/2018	10/09/2018	19/09/2018	19/09/2018		10/10/2018		
18/YH/0099	241430	A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer's Disease (AD)	Yes	01/09/2018	1	22	23	29/05/2018	09/08/2018	23/04/2018		10/08/2018		14/08/2018	I - Rare diseases	Neither
18/LO/1525	240039	Assessment of the Impact of Real-time Continuous Glucose Monitoring on People Presenting with Severe Hypoglycaemia (AIR-CGM)	Yes	03/01/2019	59	48	107	31/07/2018	18/09/2018	09/11/2018		16/11/2018			A - Permissions delayed/denied	Sponsor
															D - Sponsor Delays	
18/NE/0281	237312	Neuromuscular Electrical Stimulation(NMES) for the treatment of Diabetic Peripheral Neuropathy. A Randomised Controlled Trial	Yes	19/02/2019	0	0	0		19/02/2019	23/10/2018		19/02/2019				
18/LO/0430	241907	An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients with Relapsed Immune Thrombocytopenic Purpura	Yes	01/02/2019	28	29	57	02/03/2018	06/12/2018	11/06/2018		03/01/2019		03/01/2019	I - Rare diseases	Neither
18/LO/1187	240011	(A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy)	No		197			13/04/2018	25/07/2018		24/04/2018	07/02/2019		11/02/2019	D - Sponsor Delays	Sponsor
															G - No patients consented	
18/NS/0093	237699	Assessment of the Impact of a Personalised Nutrition Intervention in Impaired Glucose Regulation ASPIRE-DNA	Yes	26/11/2018	13	48	61	17/07/2018	26/09/2018			09/10/2018		09/10/2018		
17/WA/0420	235469	IRL790C003 Phase IIA Parkinson's Dyskinesia Study	Yes	28/08/2018	0	18	18	14/06/2018	10/08/2018			10/08/2018		16/08/2018		
17/EM/0406	235483	A Phase 1/2 Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients with Persistent/Chronic Immune Thrombocytopenia (PRTX-100-202)	No		62			20/06/2018	20/06/2018	15/01/2018	16/08/2018	21/08/2018			D - Sponsor Delays	Sponsor
18/NW/0514	249725	SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	No		26			16/07/2018	11/01/2019			06/02/2019			G - No patients consented	Neither
18/LO/1007	242697	Patient-Reported Outcomes with the Accu-Chek® Solo Micropump System vs. Multiple Daily Injection Therapy vs. mylife OmniPod® in Patients with Type 1 Diabetes	No					12/06/2018	12/06/2018					01/04/2019	A - Permissions delayed/denied	Neither
18/SW/0039	229163	Induction of labour for predicted macrosomia	No		14			29/06/2018	03/10/2018	20/03/2018	17/10/2018	17/10/2018		04/12/2018	G - No patients consented	Neither
18/EM/0112	236871	A comparison of reduced dose total body irradiation (TBI) and cyclophosphamide with fludarabine and melphalan reduced intensity conditioning in adults with acute lymphoblastic leukaemia (ALL) in complete remission	Yes	22/11/2018	45	98	143	20/06/2018	02/07/2018	12/06/2018	13/08/2018	16/08/2018		17/09/2018	D - Sponsor Delays	Sponsor
															I - Rare diseases	
18/LO/0866	224730	Prevention of hypertensive injury to the brain by intensive treatment after intracerebral haemorrhage: a pilot randomised trial of home telemetry-guided treatment	No		18			13/07/2018	28/02/2019			11/03/2019	18/03/2019	18/03/2019		

17/SS/0105	209066	Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischaemic stroke with proven acute symptomatic occlusion	No		152			15/06/2018	27/09/2018	27/04/2018		26/02/2019			D - Sponsor Delays	Sponsor
															J - Other	
18/LO/1289	245746	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.	Yes	28/11/2018	90	41	131	19/07/2018	20/07/2018	05/09/2018	18/10/2018	18/10/2018		26/11/2018	D - Sponsor Delays	Sponsor
18/NE/0214	245998	MN39158 - A Long Term Extension Study in Multiple Sclerosis	No		112			26/07/2018	18/06/2018	11/07/2018		08/10/2018		10/10/2018	J - Other	Sponsor
18/LO/1215	245798	A Randomized, Phase 3 Study of Eryaspase in Combination with Chemotherapy versus Chemotherapy Alone as Second-Line Treatment in Patients with Pancreatic Adenocarcinoma TRYbeCA-1 – TRial of erYaspase in pancreatic CAncer	No					06/07/2018	31/07/2018	22/08/2018	06/07/2018			29/03/2019	J - Other	Neither
18/ES/0071	241904	A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix or Leuprolide	No		130			22/06/2018	28/09/2018	18/10/2018	22/01/2019	05/02/2019		16/04/2019	D - Sponsor Delays	Sponsor
17/LO/1018	224051	An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies	Yes	31/12/2018	72	18	90	01/08/2018	02/10/2018	06/09/2018		13/12/2018		19/12/2018	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/0330	236942	A pragmatic, multi-centre, three-armed randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment	No		30			31/07/2018	21/08/2018	25/05/2018	20/09/2018	20/09/2018		03/04/2019	E - Staff availability issues	NHS Provid
18/EE/0260	230833	BN40031- CREAD Open Label Extension Study	Yes	27/11/2018	55	6	61	18/09/2017	27/09/2018		21/11/2018	21/11/2018		22/11/2018	D - Sponsor Delays	Sponsor
17/WM/0117	223480	Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity	No		119			10/07/2018	12/12/2018			10/04/2019			D - Sponsor Delays	Sponsor
18/LO/1709	244863	PRIME-HCC: Preliminary assessment of safety and bioactivity of the Ipilimumab and Nivolumab combination prior to liver resection (LR) in hepatocellular carcinoma (HCC)	No		13				25/01/2019		25/01/2019	07/02/2019		01/03/2019	H - Contracting delays	Neither
16/LO/1567	242092	A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the anti-PD-1 Antibody BGB-A317 versus Chemotherapy as Second Line Treatment in Patients with Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma	No		110			16/01/2018	12/10/2018		09/02/2018	30/01/2019		11/02/2019	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/SW/0219	250410	A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO DETERMINE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AG-348 IN ADULT SUBJECTS WITH NON-TRANSFUSION-DEPENDENT THALASSEMIA-AG348-C-010	No		22			29/08/2018	03/01/2019	20/11/2018		25/01/2019			F - No patients seen	Neither
															I - Rare diseases	
18/LO/1567		BGB-A317-302	No					12/10/2018	12/10/2018						Site declined to participate	
18/WA/0276	246112	Randomised Double-Blind, Placebo-Controlled (within dose groups) and Active Controlled (Eplerenone group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients with Diabetic Nephropathy	No		149			03/09/2018	03/09/2018	26/10/2018	09/01/2019	30/01/2019		08/02/2019	D - Sponsor Delays	Sponsor
18/SC/0240	230920	A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (Prodromal to Mild) Alzheimer's Disease	No		19			12/03/2018	23/11/2018		05/12/2018	12/12/2018		12/12/2018	H - Contracting delays	Neither
18/NS/0100	236463	Hand Osteoarthritis: Investigating Pain Effects in a Randomised Placebo-Controlled Feasibility Study of Estrogen-Containing Therapy	No		110			05/09/2018	14/11/2018			04/03/2019			D - Sponsor Delays	Sponsor

18/YH/0136	214921	A Multi-Centre, Pilot, Prospective, Clinical Investigation of DermaRep™ Device in the treatment of Venous Leg Ulcers.	Yes	14/02/2019	97	14	111	21/09/2018	26/10/2018	20/08/2018		31/01/2019		01/02/2019	D - Sponsor Delays	Sponsor
															H - Contracting delays	
18/LO/1911	252871	Pilot study of brain Magnetic Resonance Imaging (MRI) scans to assess bleeding risk in children with immune thrombocytopenia (ITP-low platelet count).	Yes	13/12/2018	10	13	23		20/11/2018	16/11/2018	30/11/2018	30/11/2018				
17/NE/0061	215780	Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic Stroke - A Randomised Clinical Trial of Low-Dose Colchicine for Secondary Prevention After Stroke	No		13			08/02/2018	19/02/2019	25/07/2017	06/02/2019	04/03/2019				
18/EM/0256	248467	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema following Large Hemispheric Infarction	No					30/08/2018	26/11/2018						D - Sponsor Delays	Sponsor
															J - Other	
18/SC/0444	249450	A phase 2, multi-center, open-label, randomized study of oral asciminib added to imatinib versus continued imatinib versus switch to nilotinib in patients with CML-CP who have been previously treated with imatinib and have not achieved deep molecular response - CORRECT DOCUMAS REF: 18HH4719 (deleted in error)	Yes	22/11/2018	75	1	76	01/08/2018	07/09/2018	25/09/2018	01/11/2018	21/11/2018		21/11/2018	D - Sponsor Delays	Sponsor
17/LO/1808	231108	An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy	No		128			17/10/2018	17/10/2018	18/12/2017		22/02/2019		14/03/2019	D - Sponsor Delays	Sponsor
															H - Contracting delays	
19/LO/0053	255804	A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Blind, Controlled Study of Aducanumab (BIIB037) in Subjects With Mild Cognitive Impairment due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Subjects with Asymptomatic Amyloid-Related Imaging Abnormalities	No					14/10/2018	09/01/2019						D - Sponsor Delays	Sponsor
															J - Other	
18/EE/0300	236285	PROMPT: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer	No		113			26/10/2018	08/11/2018	19/10/2018		01/03/2019		01/04/2019	D - Sponsor Delays	Sponsor
17/LO/1875	219487	An international investigator-led phase III multi-arm multi-stage multi-centre randomised controlled platform trial of adjuvant therapy in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse	No					26/09/2018	30/10/2018	08/01/2018					D - Sponsor Delays	Sponsor
															J - Other	
18/LO/1258	248312	Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BG00011 in Patients With Idiopathic Pulmonary Fibrosis	No					02/11/2018	12/11/2018					23/01/2019	D - Sponsor Delays	Sponsor
18/SO/0384	245537	A Phase I/IIa Sporozoite Challenge Study to assess the safety, immunogenicity and protective efficacy of intravenous boosting with malaria vaccine candidates ChAd63 and MVA encoding ME-TRAP	Yes	15/12/2018	26	12	38	07/11/2018	07/11/2018	01/11/2018	30/11/2018	03/12/2018		03/12/2018		
19/LO/0095	229300	Increase in colonic PPropionate as a method of prEVENTing weight gain in young adults	No		22			23/11/2018	17/01/2019	25/01/2019		08/02/2019			J - Other	Neither
18/WA/0385	254760	A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6- Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment	No					21/11/2018	21/11/2018						D - Sponsor Delays	Sponsor

18/SC/0591	250421	A Randomized, Open Label, Phase 2 Study of Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Participants with Advanced or Metastatic Solid Tumors of High Tumor of High Tumor Mutational Burden (TMB-H)	No		106			08/06/2018	22/11/2018	24/01/2019	27/07/2018	08/03/2019		13/03/2019	D - Sponsor Delays	Sponsor
18/EM/0280	245964	A FIRST IN HUMAN MULTI-CENTER, OPEN LABEL, PROSPECTIVE STUDY TO EVALUATE THE SAFETY, USABILITY AND PERFORMANCE OF THE V-LAP SYSTEM	No		37			05/12/2018	28/01/2019	27/01/2019	20/02/2019	06/03/2019				
19/YH/0013	255993	A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who have not received Previous Systemic Anticancer therapy.	No					19/11/2018	01/02/2019		29/11/2018					
19/NW/0155	255226	A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement.	No					08/03/2019	08/03/2019							
18/LO/1199	241759	Study to compare once-daily Extended Release tacrolimus Versus twice-daily Immediate Release Tacrolimus following renal allograft failure to Reduce the risk of Allosensitisation (EVITRA Trial)	Yes	14/11/2018	36	19	55	07/08/2018	20/09/2018	13/08/2018	27/03/2018	26/10/2018				
18/LO/1176	234823	PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, EFFICACY, AND SAFETY STUDY OF MTAU9937A IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	No		70			09/04/2018	11/07/2018	21/08/2018		19/09/2018			D - Sponsor Delays	Sponsor
18/LO/0900	154432	WithHolding Enteral feeds Around packed red cell Transfusion to prevent necrotising enterocolitis in preterm neonates: a multi-centre, electronic patient record (EPR), randomised controlled point-of-care pilot trial	Yes	13/11/2018	23	41	64	25/04/2018	10/09/2018	06/07/2018	03/10/2018	03/10/2018		12/11/2018		
19/LO/0083	201045	Safety and Efficacy of Prednisolone in Adrenal Insufficiency Disease (PRED-AID Study)	No					07/12/2018	11/03/2019	15/02/2019	07/12/2018			01/04/2019		
18/LO/1549	247067	A Phase II, Two-Stage, Trial of Pembrolizumab in Cancer of Unknown primary - CUPem	Yes	28/02/2019	21	24	45		14/01/2019	15/11/2018		04/02/2019		22/02/2019	G - No patients consented	Neither
18/LO/0165	224726	Avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer: A phase III randomised study	No					02/11/2018	05/11/2018	09/05/2018	02/11/2018				D - Sponsor Delays	Sponsor
17/EE/0382	220851	Predicting Outcomes From Crohn's Disease Using a Molecular Biomarker (PROFILE) Trial.	Yes	22/08/2018	40	28	68	02/01/2018	15/06/2018		12/07/2018	25/07/2018		27/07/2018	G - No patients consented	Neither
18/SC/0055	239091	Evaluating the effect of immunisation with group B meningococcal vaccines on meningococcal carriage	Yes	06/11/2018	17	39	56	10/01/2018	11/09/2018	05/03/2018	28/09/2018	28/09/2018		06/11/2018		
18/LO/1610	239718	Pilot study assessing the efficacy of Oxaliplatin based Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of colorectal peritoneal metastases deemed not suitable for cytoreduction and heated intraperitoneal chemotherapy.	No		18				08/11/2018			26/11/2018			G - No patients consented	Neither
18/LO/0106	170254	A prospective randomised controlled trial of hydroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies	No		4			05/01/2018	11/02/2019	09/03/2018	14/02/2019	15/02/2019				
18/EM/0245	242737	Phase I study of High Intensity Focused Ultrasound (HIFU) in Early Rectal Cancer	No		35			28/08/2018	16/11/2018	01/11/2018		21/12/2018			G - No patients consented	Neither
18/EM/0244	243585	A Phase II feasibility study of High Intensity Focused Ultrasound (HIFU) in late stage pelvic cancer	No		35			28/08/2018	16/11/2018	01/11/2018		21/12/2018			G - No patients consented	Neither
16/EM/0322	202096	Tenecteplase in Wake-up Ischaemic Stroke Trial	No		28			14/03/2018	10/12/2018	18/08/2017	21/11/2018	07/01/2019		21/01/2019	G - No patients consented	Neither
18/LO/0518	237346	A phase 2/3, multicentre, open-label, multi-cohort, two-part study evaluating the pharmacokinetics, safety and efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) administered with a background regimen in HIV-1 infected, treatment experienced, virologically suppressed paediatric subjects	No		112			04/04/2018	17/10/2018	25/07/2018	05/02/2019	06/02/2019			H - Contracting delays	Sponsor

18/LO/0565	241439	Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)	No		160			12/04/2018	30/05/2018	30/07/2018		06/11/2018			D - Sponsor Delays	Sponsor
18/LO/0798	237827	DNAe Diagnostic Evaluation Study	Yes	01/12/2018	81	89	170	04/06/2018	14/06/2018			03/09/2018		03/12/2018	D - Sponsor Delays	Sponsor
18/LO/1203	242451	ORBITA-2: A placebo-controlled trial of percutaneous coronary intervention for the relief of stable angina (Objective Randomized Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina 2)	Yes	08/02/2019	11	7	18	11/07/2018	21/01/2019	31/08/2018		01/02/2019				
18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Yes	11/12/2018	113	35	148	04/05/2018	16/07/2018	13/07/2018	01/11/2018	06/11/2018			D - Sponsor Delays	Sponsor
17/SC/0244	226900	A randomised, parallel-group, double-blind, double-dummy, active-controlled, multicentre study to assess the efficacy and safety of vilaprisan in subjects with uterine fibroids	Yes	16/08/2018	49	41	90	09/05/2018	18/05/2018	27/07/2017	26/06/2018	06/07/2018		10/07/2018	F - No patients seen	Sponsor
															H - Contracting delays	
18/LO/1070	174513	Improving the safety of oral immunotherapy for cow's milk allergy (The SOCMa Study)	Yes	15/08/2018	1	27	28	23/05/2018	18/07/2018	18/07/2018	19/07/2018	19/07/2018		19/07/2018		
18/YH/0223	243476	Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers when Administered Using a 1+1 Schedule in a National Immunization Schedule Having a Meningococcal Group B Vaccine as Standard of Care	No		126			07/06/2018	12/07/2018	09/07/2018	14/11/2018	15/11/2018		20/11/2018	H - Contracting delays	Sponsor
18/LO/1317	250312	Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study	Yes	26/10/2018	11	10	21	03/07/2018	05/10/2018	20/08/2018	16/10/2018	16/10/2018		22/10/2018		
18/NI/0129	218623	Efficacy and safety assessment of T4032 (unpreserved bimatoprost 0.01%) versus Lumigan® 0.01% in ocular hypertensive or glaucomatous patients.	Yes	18/03/2019	19	104	123	03/07/2018	15/11/2018	17/10/2018	20/11/2018	04/12/2018			F - No patients seen	Neither
18/LO/1400	250545	A prospective study to assess the efficacy and safety of the BlueWind RENOVA iStim™ system for the treatment of patients diagnosed with overactive bladder	No					18/07/2018	11/10/2018						D - Sponsor Delays	Sponsor
17/LO/0182	213821	A Prospective, Randomized, Multicenter Controlled Trial of CERAMENT™   G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures	Yes	28/11/2018	4	23	27	07/08/2018	01/11/2018	30/03/2017	01/11/2018	05/11/2018				
18/WA/0161	238902	An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96 weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected subjects virologically suppressed with NNRTIs resistance mutation K103N.	No		92			10/09/2018	10/09/2018		10/09/2018	11/12/2018		18/12/2018	A - Permissions delayed/denied	Neither
18/SC/0242	238151	A phase III randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients.	Yes	12/02/2019	115	15	130	03/10/2018	05/10/2018	23/08/2018		28/01/2019			H - Contracting delays	Sponsor
18/SS/0085	243640	Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): A randomised, parallelgroup, allocation concealed, controlled, open, phase 3 pragmatic clinical and cost-effectiveness trial with internal pilot	No					12/10/2018	20/12/2018						D - Sponsor Delays	Sponsor
18/EM/0311	254008	A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Study of PUL-042 Inhalation Solution in Rhinovirus-induced Symptoms in Current Smokers with Gold Stage 0 Chronic Obstructive Pulmonary Disease (COPD)	Yes	10/01/2019	6	21	27	11/10/2018	14/12/2018	14/12/2018		20/12/2018		20/12/2018		
19/LO/0067	256498	The effect of cross-linked sodium hyaluronate on the quality of optical coherence tomography imaging	No		28			11/12/2018	15/03/2019		15/03/2019	12/04/2019		12/04/2019		
18/WA/0239	243333	Delivering the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis	No		11			05/12/2018	28/01/2019	21/12/2018		08/02/2019		02/01/2019		

19/HRA/0634	258886	Mobile learning resources as a tool for improving clinician's ability to break bad news: A quasi-randomised controlled trial	No		9			28/01/2019	30/01/2019	28/01/2019	08/02/2019	08/02/2019				
19/LO/0282	259274	Investigating the utility of a complex film intervention about MS delivered online	No		14				12/03/2019	12/03/2019		26/03/2019				
18/EE/0099	239606	An open label, randomised, phase III Study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE study)	No		40			13/10/2017	15/02/2019	01/06/2018	08/12/2017	27/03/2019		28/03/2019		
17/LO/1921	236323	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION	No					23/01/2019	07/02/2019	11/12/2018						
19/SW/0028	255759	A Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease	No					05/11/2018	25/02/2019							
19/LO/0150	258058	A double-blind, placebo-controlled, randomised phase III trial to assess the safety and efficacy of Viaskin Peanut in peanut-allergic young children 1-3 years of age	No					11/10/2018	04/02/2019	11/03/2019						
18/LO/0324	220073	The VIDEO Trial: A Feasibility Randomised Control Trial of Vitrectomy Plus Standard Care Intravitreal Ranibizumab Injections versus Standard Care Intravitreal Ranibizumab injections Alone In Patients With Centre Involving Diabetic Macular Edema	No		24			16/08/2018	19/02/2019			15/03/2019				